Condition
KRAS G12A
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Recruiting2
Active Not Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05786924Phase 1Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT06917079Phase 1Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT05726864Phase 1Active Not Recruiting
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT07083479Unknown
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
Showing all 4 trials